Overview

Human Cytochrome P450 4F Enzymes and Drug Interactions

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Drug-drug interactions play an important role in clinical adverse events due to the prevalence of multi-drug therapy. Co-administration of warfarin and a statin has expanded substantially in the US over the last decades. The purpose of this study is to develop a mechanistic understanding of the role of a drug-metabolizing enzyme, CYP4F2, in the interaction between warfarin and statins. This study will test the hypothesis that lovastatin potentiates the anticoagulant effect of warfarin by inducing vitamin K-metabolizing enzyme CYP4F2 in humans, thus increasing warfarin's anticoagulant effect.
Phase:
Phase 1
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
National Institutes of Health (NIH)
Treatments:
Dihydromevinolin
L 647318
Lovastatin
Warfarin